Create a free research account to view current pricing and place an order.
How does BPC-157/TB500 work in research models?
BPC-157 is researched for tissue-repair signaling involving angiogenesis, nitric-oxide pathways, inflammatory modulation, fibroblast activity, tendon/ligament remodeling, and gastrointestinal mucosal-support mechanisms. Human pharmacokinetic and clinical standardization remain limited. TB-500 is a thymosin beta-4 fragment researched for actin-binding biology, cell migration, angiogenesis, tissue remodeling, and soft-tissue repair signaling. It is often paired conceptually with BPC-157 in regenerative protocols.
What is the half-life of BPC-157/TB500?
Half-life: Blend; component PK differs.
Blend pharmacokinetics vary by component. Operational timing should be based on the dominant pathway and the most sensitivity-prone ingredient.
Research dosing reference
1-2 mg total blend daily or protocol-specific repair exposure.
How is BPC-157/TB500 reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 5/5 mg | 2 mL BAC Water | 0.050 mg/unit |
| 10/10 mg | 2 mL BAC Water | 0.100 mg/unit |
Injection timing
Daily or split AM/PM depending on protocol objective. Local versus systemic placement should be determined by research design and clinician preference.
Beginner escalation
Start with conservative exposure to evaluate injection-site tolerance and systemic response before increasing or layering additional repair agents.
Side-effect mitigation
Monitor injection irritation, transient fatigue, headache, flushing, or unexpected inflammatory response. Rotate sites and preserve sterile technique.
Stack compatibility
Commonly paired with complementary repair pathways such as BPC-157, TB-500, GHK-Cu, KPV, or SS-31 depending on tissue target.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Acute repair protocols are commonly structured as 2-6 week focused blocks, then reassess pain, mobility, inflammatory response, and tissue objective. Maintenance, if used, should be lower-frequency and objective-driven.
Frequently asked questions
What is BPC-157/TB500 and how is it studied?
BPC-157 is researched for tissue-repair signaling involving angiogenesis, nitric-oxide pathways, inflammatory modulation, fibroblast activity, tendon/ligament remodeling, and gastrointestinal mucosal-support mechanisms. Human pharmacokinetic and clinical standardization remain limited. TB-500 is a thymosin beta-4 fragment researched for actin-binding biology, cell migration, angiogenesis, tissue remodeling, and soft-tissue repair signaling. It is often paired conceptually with BPC-157 in regenerative protocols. BPC-157/TB500 is catalogued in the Recovery / Regenerative group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of BPC-157/TB500?
Reference half-life for BPC-157/TB500: blend; component PK differs. Blend pharmacokinetics vary by component. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is BPC-157/TB500 stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is BPC-157/TB500 reconstituted for laboratory work?
The reference reconstitution for the 5/5 mg vial is 2 mL BAC Water, which gives a concentration of about 2.5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is BPC-157/TB500 FDA approved?
No. The research-grade BPC-157/TB500 described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration